BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 35489025)

  • 1. Association between medical androgen deprivation therapy and long-term cardiovascular disease and all-cause mortality in nonmetastatic prostate cancer.
    Forster RB; Engeland A; Kvåle R; Hjellvik V; Bjørge T
    Int J Cancer; 2022 Oct; 151(7):1109-1119. PubMed ID: 35489025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.
    Bosco C; Bosnyak Z; Malmberg A; Adolfsson J; Keating NL; Van Hemelrijck M
    Eur Urol; 2015 Sep; 68(3):386-96. PubMed ID: 25484142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is androgen deprivation therapy for prostate cancer associated with cardiovascular disease? A meta-analysis and systematic review.
    Liang Z; Zhu J; Chen L; Xu Y; Yang Y; Hu R; Zhang W; Song Y; Lu Y; Ou N; Liu X
    Andrology; 2020 May; 8(3):559-574. PubMed ID: 31743594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen-deprivation therapy and risk of death from cardio-vascular disease in prostate cancer patients: a nationwide lithuanian population-based cohort study.
    Jonušas J; Drevinskaitė M; Patašius A; Kinčius M; Janulionis E; Smailytė G
    Aging Male; 2022 Dec; 25(1):173-179. PubMed ID: 35882633
    [No Abstract]   [Full Text] [Related]  

  • 5. Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction.
    Nguyen PL; Chen MH; Beckman JA; Beard CJ; Martin NE; Choueiri TK; Hu JC; Hoffman KE; Dosoretz DE; Moran BJ; Salenius SA; Braccioforte MH; Kantoff PW; D'Amico AV; Ennis RD
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1411-6. PubMed ID: 21708431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does androgen-deprivation therapy increase the risk of ischemic cardiovascular and cerebrovascular diseases in patients with prostate cancer? A nationwide population-based cohort study.
    Kim DK; Lee HS; Park JY; Kim JW; Ha JS; Kim JH; Yang WJ; Cho KS
    J Cancer Res Clin Oncol; 2021 Apr; 147(4):1217-1226. PubMed ID: 33000338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies.
    Zhao J; Zhu S; Sun L; Meng F; Zhao L; Zhao Y; Tian H; Li P; Niu Y
    PLoS One; 2014; 9(9):e107516. PubMed ID: 25264674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.
    Nguyen PL; Je Y; Schutz FA; Hoffman KE; Hu JC; Parekh A; Beckman JA; Choueiri TK
    JAMA; 2011 Dec; 306(21):2359-66. PubMed ID: 22147380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged ≥66 years.
    Abdollah F; Sammon JD; Reznor G; Sood A; Schmid M; Klett DE; Sun M; Aizer AA; Choueiri TK; Hu JC; Kim SP; Kibel AS; Nguyen PL; Menon M; Trinh QD
    Eur J Surg Oncol; 2015 Nov; 41(11):1529-39. PubMed ID: 26210655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temporal trends in cardiovascular burden among patients with prostate cancer receiving androgen deprivation therapy: a population-based cohort study.
    Chan JSK; Satti DI; Lee YHA; Hui JMH; Dee EC; Ng K; Liu K; Tse G; Ng CF
    Br J Cancer; 2023 Jun; 128(12):2253-2260. PubMed ID: 37076564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study.
    Haque R; UlcickasYood M; Xu X; Cassidy-Bushrow AE; Tsai HT; Keating NL; Van Den Eeden SK; Potosky AL
    Br J Cancer; 2017 Oct; 117(8):1233-1240. PubMed ID: 29017178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients With Prostate Cancer Based on Existence of Cardiovascular Risk.
    Dragomir A; Touma N; Hu J; Perreault S; Aprikian AG
    J Natl Compr Canc Netw; 2023 Feb; 21(2):163-171. PubMed ID: 36791755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.
    Basaria S; Muller DC; Carducci MA; Egan J; Dobs AS
    Cancer; 2006 Feb; 106(3):581-8. PubMed ID: 16388523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.
    O'Farrell S; Garmo H; Holmberg L; Adolfsson J; Stattin P; Van Hemelrijck M
    J Clin Oncol; 2015 Apr; 33(11):1243-51. PubMed ID: 25732167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Null association between androgen-deprivation therapy and nonprostate cancer mortality among older men with nonmetastatic prostate cancer.
    Wallis CJD; Satkunasivam R; Herschorn S; Law C; Seth A; Kodama RT; Kulkarni GS; Nam RK
    Urol Oncol; 2018 May; 36(5):241.e1-241.e6. PubMed ID: 29503141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of Dementia and Depression in Young and Middle-aged Men Presenting with Nonmetastatic Prostate Cancer Treated with Androgen Deprivation Therapy.
    Tully KH; Nguyen DD; Herzog P; Jin G; Noldus J; Nguyen PL; Kibel AS; Sun M; McGregor B; Basaria S; Trinh QD
    Eur Urol Oncol; 2021 Feb; 4(1):66-72. PubMed ID: 31624049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?
    Keating NL; O'Malley AJ; Freedland SJ; Smith MR
    Eur Urol; 2013 Jul; 64(1):159-66. PubMed ID: 22537796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer.
    Nguyen C; Lairson DR; Swartz MD; Du XL
    Pharmacotherapy; 2018 Oct; 38(10):999-1009. PubMed ID: 30080934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care.
    Martín-Merino E; Johansson S; Morris T; García Rodríguez LA
    Drug Saf; 2011 Nov; 34(11):1061-77. PubMed ID: 21981434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19.
    Schmidt AL; Tucker MD; Bakouny Z; Labaki C; Hsu CY; Shyr Y; Armstrong AJ; Beer TM; Bijjula RR; Bilen MA; Connell CF; Dawsey SJ; Faller B; Gao X; Gartrell BA; Gill D; Gulati S; Halabi S; Hwang C; Joshi M; Khaki AR; Menon H; Morris MJ; Puc M; Russell KB; Shah NJ; Sharifi N; Shaya J; Schweizer MT; Steinharter J; Wulff-Burchfield EM; Xu W; Zhu J; Mishra S; Grivas P; Rini BI; Warner JL; Zhang T; Choueiri TK; Gupta S; McKay RR
    JAMA Netw Open; 2021 Nov; 4(11):e2134330. PubMed ID: 34767021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.